查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1827949

隱球菌病藥物市場（按藥物類別、最終用戶、給藥途徑、分銷管道和患者類型）—2025-2032 年全球預測

Cryptococcosis Treatment Market by Drug Class, End User, Administration Route, Distribution Channel, Patient Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年隱球菌病治療市場將成長至 125 億美元，複合年成長率為 6.12%。

主要市場統計數據
基準年2024年 77.7億美元
預計2025年 82.4億美元
預測年份：2032年 125億美元
複合年成長率（%） 6.12%

清晰的策略概述，概括了當今隱球菌病治療市場的臨床複雜性、供應鏈現實和相關人員的要求

隱球菌病仍然是臨床上重要的真菌感染疾病，尤其影響免疫力缺乏的人群，引起了臨床醫生、採購專業人員和政策制定者的持續關注。有限的有效藥物、複雜的給藥要求、不斷變化的抗藥性模式以及合併症管理決定了疾病的治療前景。因此，相關人員必須將臨床最佳實踐與現實世界的限制因素（例如藥物可及性、給藥途徑考慮因素以及患者特定因素）相協調。

近年來，醫療體系已轉向更具韌性的供應鏈，並更緊密地銜接醫院處方和門診病人治療路徑。這些轉變影響了處方行為和醫療機構的準備情況，尤其是在管理大量HIV感染者和移植患者的機構。因此，決策者面臨雙重挑戰：既要確保患者持續獲得第一線治療和補救性治療，又要最佳化不同臨床環境下的治療效果。本引言概述了臨床必要性與操作可行性之間的核心矛盾，為後續更詳細的分析奠定了基礎。

臨床創新、供應鏈重組和管理主導護理如何重新定義隱球菌病藥物途徑和相關人員的角色

藥物治療的進步、強調抗菌藥物管理的監管環境以及全球醫藥供應鏈的結構性變化，正在改變隱球菌病的治療模式。新型抗真菌製劑和改進的脂質體遞送系統正在重塑重症疾病的治療方案，而對抗真菌藥物管理的日益重視也正在改善臨床醫生在住院和門診的治療順序。同時，製造商正在適應價格壓力和不斷變化的報銷模式，這影響了對生產能力和製劑創新的投資。

藥物傳遞和診斷技術的發展正在影響治療途徑。快速診斷和改進的生物標記監測技術使早期發現成為可能，從而可能改變治療持續時間和強度。在臨床創新的同時，衛生系統正在優先考慮供應商多元化和庫存彈性，鼓勵對本地製造和策略協議的投資。總而言之，這些動態正在為隱球菌病治療創造一個更細緻入微、臨床響應更靈敏的環境，這需要臨床團隊、供應鏈經理和商業性相關人員的全面響應。

評估 2025 年關稅環境如何加強整個抗真菌供應鏈的供應鏈重組、籌資策略和區域製造準備

2025年實施的關稅調整的累積影響凸顯了現有供應鏈的脆弱性，並加速了製造商、經銷商和醫療保健系統的戰略應對。原料藥、專用脂質體輔料和成品製​​劑的進口成本不斷上升，給採購預算帶來了壓力，並促使最終用戶尋求替代籌資策略。為此，製造商正在重新評估製造地和採購政策，以減輕關稅波動的影響並維持關鍵抗真菌藥物的供應。

因此，一些供應商加快了本地化和雙重採購力度，投資區域生產基地或增加製造外包以保持供應的連續性。雖然這些措施降低了單一來源風險，但它們需要更多時間進行資本投資、監管部門核准和新設施資格認證。對於採購商而言，關稅情況導致對供應商績效的審查更加嚴格，並增加使用具有價格穩定機制的長期合約。臨床醫生和藥房負責人也重新評估了他們的庫存政策，在即時採購和戰略緩衝庫存之間取得平衡，以應對短期中斷。總體而言，關稅環境引發了結構性變化，促使相關人員採取更具彈性（儘管有時成本更高）的方法來確保不間斷地獲得治療。

與藥物類別、臨床環境、給藥途徑、分銷管道和患者類型相關的詳細細分分析可區分治療和獲取動態

細分分析揭示了治療層級、治療環境、給藥途徑、分銷管道和患者類型之間的不同動態，每種動態對臨床實踐和商業化都有不同的影響。依藥物類別，對Azole、Flucytosine和Polyenes市場進行了研究。在Azole中，進一步探討了Fluconazole、Posaconazole和Voriconazole等特定藥物的市場；而在Polyenes中，重點關注兩性Amphotericin B脫氧膽酸鹽和Amphotericin B脂質體。這些區別有助於臨床選擇，因為口服Azole支持長期抑制和門診管理，而Polyenes和Flucytosine是誘導和升級方案的核心。

目錄

第1章 引言

第2章分析方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 脂質體Amphotericin B製劑在改善中樞神經系統滲透的進展。
  • 評估新型三唑衍生物對抗抗藥性隱球菌菌株療效的臨床試驗
  • 在資源有限的環境中整合快速分子診斷檢測以早期檢測隱球菌抗原
  • 利用免疫調節劑增強隱球菌病患者宿主反應的新型聯合治療
  • 以長效注射抗黴菌藥物提高 HIV 相關隱球菌腦膜炎患者的藥物順從性
  • 人們越來越重視隱球菌抗原進行分散的就地檢驗，以實現以地區為基礎的篩檢。
  • 開發一種針對腦內新型隱球菌的奈米粒子藥物輸送系統
  • 促進創新隱球菌病療法獲得孤兒藥認定的監管策略

第6章：美國關稅的累積影響（2025年）

第7章：人工智慧（AI）的累積影響（2025年）

8. 隱球菌病藥物市場（依藥物類別）

  • Azole
    • Fluconazole
    • Posaconazole
    • Voriconazole
  • Flucytosine
  • Polyenes
    • Amphotericin B脫氧膽酸鹽
    • 脂質體兩性黴素B

9. 隱球菌病藥物市場（依最終用戶分類）

  • 診所
    • 門診
    • 專科診所
  • 居家護理
  • 醫院

第 10 章隱球菌病藥物市場（依給藥途徑）

  • 靜脈
    • 中心靜脈導管
    • 周邊靜脈
  • 口服
    • 暫停
    • 藥片

第 11 章隱球菌病藥物市場（按分銷管道）

  • 離線
  • 線上

第 12 章：隱球菌病藥物市場（依患者類型）

  • HIV感染者
  • 未感染愛滋病毒者
    • 正常免疫功能
    • 移植患者

第 13 章：隱球菌病藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章。隱球菌病藥物市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。各國隱球菌病藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 市佔率分析（2024年）
  • FPNV定位矩陣（2024年）
  • 競爭分析
    • Pfizer Inc.
    • Gilead Sciences, Inc.
    • Bausch Health Companies Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Astellas Pharma Inc.
    • Cipla Limited
    • Dr. Reddy's Laboratories Ltd.
    • Sun Pharmaceutical Industries Limited
    • Lupin Limited
Product Code: MRR-4316E4E894B8

The Cryptococcosis Treatment Market is projected to grow by USD 12.50 billion at a CAGR of 6.12% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.77 billion
Estimated Year [2025] USD 8.24 billion
Forecast Year [2032] USD 12.50 billion
CAGR (%) 6.12%

A clear and strategic overview that frames the clinical complexity, supply chain realities, and stakeholder imperatives shaping cryptococcosis treatment today

Cryptococcosis remains a clinically significant fungal infection that disproportionately affects immunocompromised populations, prompting sustained attention from clinicians, procurement specialists, and policy makers. The therapeutic landscape is shaped by a limited number of efficacious agents, complex administration requirements, and evolving patterns of resistance and co-morbidity management. As a result, stakeholders must reconcile clinical best practices with real-world constraints such as drug availability, route-of-administration considerations, and patient-specific factors.

In recent years, health systems have reoriented toward more resilient supply chains and closer alignment between hospital formularies and outpatient care pathways. These shifts have influenced prescribing behavior and institutional preparedness, especially in settings that manage high volumes of HIV-infected and transplant patients. Consequently, decision-makers face a dual imperative: ensuring uninterrupted access to first-line and salvage therapies while optimizing outcomes across diverse clinical settings. This introduction frames the core tension between clinical necessity and operational feasibility, establishing the foundation for the more detailed analyses that follow.

How clinical innovation, supply chain reconfiguration, and stewardship-driven practices are jointly redefining cryptococcosis therapy pathways and stakeholder roles

The landscape for cryptococcosis treatment is undergoing transformative shifts driven by advances in pharmacotherapy, regulatory emphasis on antimicrobial stewardship, and structural changes in global pharmaceutical supply chains. Newer antifungal formulations and improved liposomal delivery systems have reshaped treatment options for severe disease, while heightened attention to antifungal stewardship is refining how clinicians sequence therapies across inpatient and outpatient settings. At the same time, manufacturers are adapting to pricing pressures and evolving reimbursement models, which influence investment in manufacturing capacity and formulation innovation.

Technological developments in drug delivery and diagnostics are influencing care pathways. Rapid diagnostics and improved biomarker monitoring enable earlier detection and may alter the duration and intensity of therapy, which in turn affects demand dynamics across administration routes. Parallel to clinical innovation, health systems are prioritizing supplier diversification and inventory resilience, prompting investments in local manufacturing and strategic contracting. Taken together, these dynamics are converging to create a more nuanced, clinically responsive environment for cryptococcosis treatment that requires integrated responses across clinical teams, supply chain managers, and commercial stakeholders.

Assessing how the 2025 tariff environment has intensified supply chain realignment, procurement strategies, and regional manufacturing responses across antifungal supply chains

The cumulative impact of tariff adjustments instituted in 2025 has accentuated pre-existing supply chain vulnerabilities and accelerated strategic responses among manufacturers, distributors, and health systems. Higher import costs for active pharmaceutical ingredients, specialized liposomal excipients, and finished drug products have increased pressure on procurement budgets and encouraged end users to seek alternative sourcing strategies. In response, manufacturers have re-evaluated their manufacturing footprints and sourcing policies to mitigate exposure to tariff volatility and to preserve access to critical antifungal agents.

Consequently, some suppliers have accelerated localization and dual-sourcing initiatives, investing in regional production hubs and qualifying additional contract manufacturers to maintain continuity of supply. These actions reduce single-source exposure but require capital expenditure, regulatory approvals, and time to qualify new facilities. For purchasers, the tariff landscape has prompted more stringent supplier performance monitoring and an increased use of long-term agreements with price-stability mechanisms. Clinicians and pharmacy leaders have also revisited inventory policies, balancing just-in-time procurement with strategic buffer stocks to manage short-term disruptions. Overall, the tariff environment has served as a catalyst for structural change, encouraging stakeholders to adopt more resilient, albeit sometimes costlier, approaches to ensuring uninterrupted access to treatment.

In-depth segmentation insights tying drug classes, clinical settings, administration routes, distribution channels, and patient types to differentiated treatment and access dynamics

Segmentation analysis reveals differentiated dynamics across therapeutic classes, care settings, administration routes, distribution channels, and patient types, each of which carries distinct implications for clinical practice and commercialization. Based on drug class, the market is studied across Azoles, Flucytosine, and Polyenes; within Azoles, the landscape is further examined through specific agents such as Fluconazole, Posaconazole, and Voriconazole, while Polyenes merit attention for both Amphotericin B Deoxycholate and Liposomal Amphotericin B formulations. These distinctions inform clinical choice, as oral azoles support long-term suppression and outpatient management, whereas polyene formulations and flucytosine are central to induction and severe disease protocols.

Based on End User, the market is studied across Clinics, Home Care, and Hospitals; Clinics are further differentiated into Outpatient Clinics and Specialist Clinics, reflecting where patients interface with structured monitoring and initiation of therapy. Based on Administration Route, the market is studied across Intravenous and Oral; Intravenous administration is further parsed into Central Line and Peripheral options, while Oral delivery is evaluated by Suspension and Tablet formulations. These nuances affect logistics, nursing resource allocation, and patient adherence strategies. Based on Distribution Channel, the market is studied across Offline and Online, highlighting the growing role of e-commerce and specialty pharmacy channels in improving outpatient access. Finally, based on Patient Type, the market is studied across HIV Infected and Non-HIV Infected populations; Non-HIV Infected groups are further segmented into Immunocompetent and Transplant Patients, each presenting distinct comorbidity profiles and therapeutic risk-benefit calculations. Integrating these segmentation lenses enables a granular understanding of usage patterns, formulary decisions, and the operational trade-offs that guide therapy selection across care settings.

How regional clinical imperatives, regulatory diversity, and manufacturing footprints interact to shape access, procurement, and treatment choices across major global markets

Regional dynamics exert a decisive influence on treatment availability, procurement practices, and clinical management paradigms. In the Americas, policy emphasis on hospital preparedness and the presence of large tertiary care centers shape demand for parenteral induction therapies and influence contract negotiations with manufacturers. Transitioning care from inpatient to outpatient settings is a key priority, and this reshapes how clinicians and pharmacists manage step-down therapy and adherence support.

In Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable health infrastructure create a mosaic of access realities. Countries with advanced diagnostics and reimbursement pathways have adopted newer formulations more rapidly, while resource-constrained settings prioritize cost-effective, readily available agents and pragmatic protocols that account for limited inpatient capacity. Cross-border procurement and donor-supported supply channels remain important in many jurisdictions. In the Asia-Pacific region, manufacturing capacity, particularly for generic azoles and certain APIs, is concentrated in a handful of producer countries, influencing regional supply dynamics and pricing. At the same time, several health systems are investing in diagnostic capacity and regional distribution networks to improve early detection and outpatient continuity of care. These regional patterns highlight the need for strategies tailored to local regulatory, clinical, and supply-chain contexts, while acknowledging the transnational nature of manufacturing and distribution interdependencies.

Competitive positioning and capability analysis of manufacturers, distributors, and service providers that are reshaping therapeutic access and clinical adoption in cryptococcosis care

Key companies operating in this therapeutic area are differentiated by their capabilities in formulation expertise, sterile manufacturing, global distribution networks, and regulatory compliance. Some manufacturers have invested heavily in liposomal formulation technology to improve tolerability and reduce nephrotoxicity, which has implications for uptake in intensive care and transplant units. Other firms have differentiated through robust generics portfolios and extensive API sourcing arrangements that support cost-competitive supply to outpatient and resource-constrained settings.

Distributors and specialty pharmacies play a pivotal role in bridging hospital and community care, particularly where complex intravenous therapies transition to home infusion or ambulatory infusion centers. Clinical service providers and contract manufacturers that can ensure consistent quality, scalable production, and accelerated regulatory filing pathways are increasingly valuable partners. In addition, diagnostic and digital health firms that enable earlier detection and remote monitoring contribute to more efficient treatment pathways. Overall, organizational strength is defined by the ability to integrate clinical evidence, manufacturing reliability, and responsive commercial models to support both acute-care induction and long-term suppression strategies across diverse patient populations.

Actionable strategic recommendations for leaders to strengthen supply resilience, align portfolios with clinical pathways, and optimize commercialization across care transitions

Industry leaders should prioritize a set of actionable strategies that align clinical priorities with resilient supply and adaptive commercial models. First, investing in manufacturing dual-sourcing and regional production capacity will reduce single-source risk and mitigate trade-related volatility. Second, aligning product portfolios with care pathway requirements-such as ensuring availability of both intravenous induction options and oral consolidation therapies-will support continuity across inpatient and outpatient settings. Third, strengthening partnerships with specialty pharmacies and home-infusion providers will facilitate safe transitions of care and improve adherence for long-term suppression regimens.

Moreover, leaders should embed robust stewardship and diagnostics into their commercialization plans to support appropriate use and to protect clinical efficacy. Contracting strategies that include price-stability clauses, inventory sharing arrangements, and outcomes-linked agreements can stabilize procurement budgets while maintaining access. Finally, targeted investments in clinician education, formulary support, and patient adherence programs will accelerate uptake in appropriate settings and improve outcomes. Collectively, these recommendations provide a pragmatic blueprint for converting strategic insight into operational resilience and improved patient care.

A transparent mixed-methods research approach combining clinician and supply-chain interviews with regulatory and technical literature to validate actionable insights

This research synthesizes primary and secondary inputs to produce a comprehensive understanding of clinical practice, supply-chain dynamics, and commercial behaviors. Primary research included structured interviews with clinicians, pharmacy directors, procurement officers, and manufacturing and distribution executives to capture real-world operational challenges, therapeutic decision drivers, and procurement practices. These qualitative insights were supplemented by secondary analysis of peer-reviewed clinical literature, regulatory guidance, product labels, and public-domain manufacturing and trade data to ensure technical accuracy and contextual depth.

Triangulation methods were applied to reconcile divergent perspectives and to validate recurring patterns across geographies and care settings. Where appropriate, regulatory timelines and manufacturing capacity constraints were mapped against clinical treatment protocols to identify potential bottlenecks and points of intervention. The methodology prioritized transparency in assumptions and robustness in cross-validation to ensure that conclusions reflect observable trends and expert judgment rather than speculative projection.

A concise synthesis emphasizing coordinated action across manufacturing, clinical, and procurement stakeholders to secure treatment access and optimize patient outcomes

In summary, cryptococcosis treatment is situated at the intersection of clinical complexity and operational fragility, requiring coordinated action across manufacturers, health systems, and clinical teams. Therapeutic choices hinge on drug class selection, administration route feasibility, and patient-specific factors, while access is shaped by regional manufacturing footprints, procurement strategies, and evolving trade policies. The cumulative pressures from tariff shifts and supply-chain realignments underscore the necessity of proactive risk management, including diversified sourcing and closer integration between inpatient and outpatient care channels.

Looking ahead, organizations that invest in resilient manufacturing, targeted clinical education, robust stewardship, and strategic partnerships will be best positioned to sustain access and improve clinical outcomes. By translating analytical insight into pragmatic interventions-ranging from contracting innovations to diagnostic-enabled care pathways-stakeholders can navigate the complex landscape more effectively and ensure that patients receive timely, evidence-based therapy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in liposomal amphotericin B formulations to improve central nervous system penetration
  • 5.2. Clinical trials evaluating the efficacy of novel triazole derivatives against resistant Cryptococcus strains
  • 5.3. Integration of rapid molecular diagnostic assays for early detection of cryptococcal antigen in resource limited settings
  • 5.4. Emerging combination therapies leveraging immunomodulators to enhance host response in cryptococcosis patients
  • 5.5. Adoption of long acting injectable antifungal agents to improve adherence in HIV associated cryptococcal meningitis
  • 5.6. Increasing focus on decentralized point of care testing for cryptococcal antigen to enable community based screening
  • 5.7. Development of nanoparticle based drug delivery systems to target Cryptococcus neoformans in the brain
  • 5.8. Regulatory strategies accelerating orphan drug designation for innovative cryptococcosis therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cryptococcosis Treatment Market, by Drug Class

  • 8.1. Azoles
    • 8.1.1. Fluconazole
    • 8.1.2. Posaconazole
    • 8.1.3. Voriconazole
  • 8.2. Flucytosine
  • 8.3. Polyenes
    • 8.3.1. Amphotericin B Deoxycholate
    • 8.3.2. Liposomal Amphotericin B

9. Cryptococcosis Treatment Market, by End User

  • 9.1. Clinics
    • 9.1.1. Outpatient Clinics
    • 9.1.2. Specialist Clinics
  • 9.2. Home Care
  • 9.3. Hospitals

10. Cryptococcosis Treatment Market, by Administration Route

  • 10.1. Intravenous
    • 10.1.1. Central Line
    • 10.1.2. Peripheral
  • 10.2. Oral
    • 10.2.1. Suspension
    • 10.2.2. Tablet

11. Cryptococcosis Treatment Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Cryptococcosis Treatment Market, by Patient Type

  • 12.1. HIV Infected
  • 12.2. Non-HIV Infected
    • 12.2.1. Immunocompetent
    • 12.2.2. Transplant Patients

13. Cryptococcosis Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cryptococcosis Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cryptococcosis Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Pfizer Inc.
    • 16.3.2. Gilead Sciences, Inc.
    • 16.3.3. Bausch Health Companies Inc.
    • 16.3.4. Teva Pharmaceutical Industries Ltd.
    • 16.3.5. Viatris Inc.
    • 16.3.6. Astellas Pharma Inc.
    • 16.3.7. Cipla Limited
    • 16.3.8. Dr. Reddy's Laboratories Ltd.
    • 16.3.9. Sun Pharmaceutical Industries Limited
    • 16.3.10. Lupin Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CRYPTOCOCCOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CRYPTOCOCCOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CRYPTOCOCCOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POSACONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POSACONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POSACONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POSACONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POSACONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POSACONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY VORICONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY VORICONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY VORICONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY VORICONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY VORICONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY VORICONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCYTOSINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCYTOSINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCYTOSINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCYTOSINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCYTOSINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCYTOSINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AMPHOTERICIN B DEOXYCHOLATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AMPHOTERICIN B DEOXYCHOLATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AMPHOTERICIN B DEOXYCHOLATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AMPHOTERICIN B DEOXYCHOLATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AMPHOTERICIN B DEOXYCHOLATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AMPHOTERICIN B DEOXYCHOLATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY LIPOSOMAL AMPHOTERICIN B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY LIPOSOMAL AMPHOTERICIN B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY LIPOSOMAL AMPHOTERICIN B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY LIPOSOMAL AMPHOTERICIN B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY LIPOSOMAL AMPHOTERICIN B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY LIPOSOMAL AMPHOTERICIN B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SPECIALIST CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SPECIALIST CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SPECIALIST CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SPECIALIST CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CENTRAL LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CENTRAL LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CENTRAL LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CENTRAL LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CENTRAL LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CENTRAL LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PERIPHERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PERIPHERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PERIPHERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PERIPHERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PERIPHERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PERIPHERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HIV INFECTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HIV INFECTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HIV INFECTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HIV INFECTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HIV INFECTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HIV INFECTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TRANSPLANT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TRANSPLANT PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TRANSPLANT PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TRANSPLANT PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TRANSPLANT PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TRANSPLANT PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILL